Stabilized composition for treating psoriasis

A storage stable ointment suitable for treating psoriasis comprising:

• (a) about 0.001 to about 0.01 percent by weight of a vitamin D compound;
• (b) about 0.01 to about 0.1 percent by weight of a corticosteroid;
• (c) about 0.001 to about 0.01 percent by weight of tocopherol;
• and
• (d) about 0.1 to about 5 percent by weight of an N,N-di(C1-C8)alkylamino substituted, (C4-C18)alkyl(C2-C18)carboxylic ester a (C1-C4)-alkyl(C8-C22)carboxylic ester;
• in a petrolatum carrier, and optionally containing mineral oil.

A storage stable ointment suitable for treating psoriasis comprising:

• (a) about 0.001 to about 0.01 percent by weight of calcipotriene;
• (b) about 0.01 to about 0.1 percent by weight of a corticosteroid selected from the group consisting of clobetasol propionate and betamethasone dipropionate;
• (c) about 0.001 to about 0.01 percent by weight of tocopherol;
• and
• (d) about 0.1 to about 5 percent by weight of dodecyl 2-(N,N-dimethylamino)-propionate (DDAIP);
• in a petrolatum carrier, and containing up to about 10 percent by weight mineral oil.